findmyKOL
Clinical trialNCT00000539CompletedPhase 3Interventional

Arterial Disease Multifactorial Intervention Trial (ADMIT)

SponsorNational Heart, Lung, and Blood Institute (NHLBI)Arterial Occlusive DiseasesCardiovascular DiseasesDiabetes MellitusHeart DiseasesVascular Diseases
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

To evaluate, in asymptomatic and symptomatic participants with peripheral arterial disease, the feasibility of recruitment and adherence, efficacy and safety of HDL-C raising along with effective control of LDL-C levels, antioxidant therapy, antithrombotic therapy, and their combinations.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

No facility list is in our current data snapshot for this study. The registry record on ClinicalTrials.gov ↗ carries any published locations. Why? →

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Beta caroteneNiacinPravastatinAscorbic acidVitamin EWarfarin
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
30 Sept 1992
Primary completion
—
Completion
31 Mar 1999
Last update posted
12 Jul 2016
Registered enrollment
—
Registry id
NCT00000539
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.